CRISPR Therapeutics AG CRSP
CRISPR Therapeutics AG (Nasdaq: CRSP) is a hematology drug developer. Its lead program, CASGEVY (exagamglogene autotemcel), is in Phase 2 for sickle cell disease and transfusion-dependent beta thalassemia.
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| CASGEVY (exa-cel), with Vertex | SCD and TDT (ages 2+ in US as of July 2026) | gene therapy | Approved |
| zugocabtagene geleucel (zugo-cel, CTX112) | relapsed/refractory B-cell malignancies; autoimmune diseases (SLE, systemic sclerosis, myositis, ITP, wAIHA, neurologic) | cell therapy | Phase 2 |
| CTX611 (FXI siRNA, with Sirius) | anticoagulation, incl. total knee arthroplasty | RNA (siRNA/ASO/mRNA) | Phase 2 |
| CTX310 (ANGPTL3) | HeFH, HoFH, mixed dyslipidemias, severe hypertriglyceridemia | gene therapy | Phase 1 |
| CTX340 (angiotensinogen) | refractory hypertension | gene therapy | Phase 1 |
| CTX460 (SERPINA1, SyNTase) | alpha-1 antitrypsin deficiency | gene therapy | Phase 1 |
| CTX321 (LPA) | elevated Lp(a) | gene therapy | Pre-clinical |
| CTX213 | type 1 diabetes (iPSC-derived islet cells) | cell therapy | Pre-clinical |
Recent results and decisions
- Aug 3, 2026approval FDA approved CASGEVY for children 2 years and older with SCD or TDT, 53 days post filing (label expansion).
The U.S. FDA recently approved CASGEVY in children 2 years of age and older with SCD or TDT, the first genetic therapy indicated for children as young as 2 years for both SCD and TDT.
Filing - Aug 3, 2026submitted Ex-US regulatory submissions (Saudi Arabia and UK) completed for CASGEVY in children 5-11.
Regulatory submissions have also been completed for CASGEVY in the Kingdom of Saudi Arabia (KSA) and the United Kingdom (U.K.) for the treatment of children 5 to 11 years of age.
Filing - May 4, 2026positive Update: first and second SLE patients remained in DORIS remission through Month 12 and Month 6; over 14 autoimmune patients dosed.
The previously disclosed first and second SLE patients remained in DORIS remission through Month 12 and Month 6, respectively.
Filing
2 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 hematology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.